Ori Biotech
United Kingdom
- London, England
- 18/01/2022
- Series B
- $100,000,000
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments.
By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing.
So complex manufacturing challenges can be put where they belong – in the past.
- Industry Automation Machinery Manufacturing
- Website https://oribiotech.com/
- LinkedIn https://www.linkedin.com/company/oribiotech-ltd/about/
Related People
Jason C. FosterFounder
United Kingdom -
London, England
Leveraging my commercial expertise and detailed knowledge of the UK, US and EU healthcare markets, I help build organizations that maximize the value of their products & services to improve health and achieve significant returns for investors.
Elly | $8,000,000 | (Feb 26, 2026)
Profitmind | $9,000,000 | (Feb 26, 2026)
Abram Scientific | $11,750,000 | (Feb 26, 2026)
Allica Bank | $155,000,000 | (Feb 26, 2026)
Sinergy Flow | $8,273,230 | (Feb 26, 2026)
Quill Meetings | $6,500,000 | (Feb 26, 2026)
Avisi Technologies | $10,700,000 | (Feb 26, 2026)
TBD | $3,000,000 | (Feb 26, 2026)
NationGraph | $18,000,000 | (Feb 26, 2026)
Cicada | $13,500,000 | (Feb 26, 2026)
Koah | $20,500,000 | (Feb 25, 2026)
Nimble | $47,000,000 | (Feb 25, 2026)